BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
20 March 2024 - 9:00PM
UK Regulatory
BioNTech Announces Appointment of Annemarie Hanekamp to Management
Board as Chief Commercial Officer
Mainz, Germany, March 20, 2024 (GLOBE
NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the
Company”) announced today that the Supervisory Board has appointed
Annemarie Hanekamp to the Management Board as Chief Commercial
Officer effective July 1, 2024. She will join BioNTech from
Novartis AG (“Novartis”) and succeed Sean Marett in this role.
Annemarie Hanekamp is a seasoned pharmaceutical
executive experienced in developing patient-focused commercial
strategies for innovative oncology products encompassing sales,
marketing and market access. In her new role, she will drive and
execute the global commercialization strategy to leverage
BioNTech’s full potential as a vertically integrated
biopharmaceutical company. Annemarie Hanekamp will be responsible
for building a global commercial team in preparation of BioNTech’s
first oncology product launch planned in 2026 and with a focus on
the Company’s lead product candidates in anticipation of ten
potential indication approvals by 2030.
“Annemarie Hanekamp is an accomplished leader
with a track record of more than a dozen successful product
launches, including first-time product launches in the solid tumor
field across multiple cancer types relevant to BioNTech, such as
lung, breast, gastrointestinal, prostate and bladder,” said
Helmut Jeggle, Chairman of the Supervisory Board. “She
brings a deep understanding of commercialization of oncological
products in the United States as well as in key markets in Europe.
In addition, she achieved launch readiness on an accelerated
timeline in her former role, which makes her a great fit for
BioNTech. Today, the Company is uniquely positioned to continue its
success story and transformation into a multi-product company. We
look forward to welcoming Annemarie Hanekamp to the Management
Board as we continue our work towards improving treatment options
for patients and providers.”
“Over the past 15 years, BioNTech has made
incredible progress in translating science into survival. I believe
its COVID-19 vaccine will only be the beginning of a series of
approved products to follow in the years to come,” said
Annemarie Hanekamp, designated Chief Commercial Officer at
BioNTech. “Throughout my career, I have seen firsthand the
importance of novel cancer treatments to help address unmet medical
needs for patients around the world. The co-founders’ vision and
the potential of the pipeline provides the Company with the unique
opportunity to introduce a diversified toolbox improving the
outcome for cancer patients. I look forward to working with the
teams to bring innovative therapies with combinational potential to
the market, creating an added value for patients and the society as
well as for BioNTech and its shareholders."
Annemarie Hanekamp brings a wealth of strategic
and operational expertise to BioNTech. She has more than 20 years
of experience in the healthcare industry, including 15 years of
commercial experience in companies ranging from early-stage
biotechnology companies to full-scale pharmaceutical companies. She
successfully delivered significant value in a broad range of roles:
At Novartis, she led the U.S. and global teams through a time of
strategic opportunities and operational headwinds following an
unprecedented strong launch uptake of their novel treatment for
prostate cancer. She was also responsible for building a new global
oncology organization following a company-wide transformation. At
Bristol-Myers Squibb Co., she held a pivotal role in evolving the
company’s U.S. oncology strategy, resulting in significant and
sustainable growth including an expanded market access as well as
product launches.
Annemarie Hanekamp is a Dutch citizen and holds
degrees in biomedical sciences as well as organizational
leadership.
About BioNTech
Biopharmaceutical New Technologies (BioNTech) is a global next
generation immunotherapy company pioneering novel therapies for
cancer and other serious diseases. BioNTech exploits a wide array
of computational discovery and therapeutic drug platforms for the
rapid development of novel biopharmaceuticals. Its broad portfolio
of oncology product candidates includes individualized and
off-the-shelf mRNA-based therapies, innovative chimeric antigen
receptor (CAR) T cells, several protein-based therapeutics,
including bispecific immune checkpoint modulators, targeted cancer
antibodies and antibody-drug conjugate (ADC) therapeutics, as well
as small molecules. Based on its deep expertise in mRNA vaccine
development and in-house manufacturing capabilities, BioNTech and
its collaborators are developing multiple mRNA vaccine candidates
for a range of infectious diseases alongside its diverse oncology
pipeline. BioNTech has established a broad set of relationships
with multiple global and specialized pharmaceutical collaborators,
including Biotheus, DualityBio, Fosun Pharma, Genentech, a member
of the Roche Group, Genevant, Genmab, OncoC4, Pfizer and
Regeneron.
For more information, please visit
www.BioNTech.com
Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, as
amended, including, but not be limited to, statements concerning:
expected changes to BioNTech’s leadership and the potential
benefits of BioNTech’s leadership hires; BioNTech’s research and
development programs; BioNTech’s focus on building commercial
capabilities for potential market launches; and BioNTech’s
expectations regarding the timing of, ability to obtain and
maintain regulatory approval of, and planned readiness for, such
launches. In some cases, forward-looking statements can be
identified by terminology such as “will,” “may,” “should,”
“expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,”
“estimates,” “predicts,” “potential,” “continue,” or the negative
of these terms or other comparable terminology, although not all
forward-looking statements contain these words. The forward-looking
statements in this press release are neither promises nor
guarantees, and you should not place undue reliance on these
forward-looking statements because they involve known and unknown
risks, uncertainties and other factors, many of which are beyond
BioNTech’s control and which could cause actual results to differ
materially from those expressed or implied by these forward-looking
statements. These risks and uncertainties include, but are not
limited to: discussions with regulatory agencies regarding timing
and requirements for additional clinical trials; the ability to
produce comparable clinical results in future clinical trials;
competition related to BioNTech’s product candidates, including
those with different mechanisms of action and different
manufacturing and distribution constraints, on the basis of, among
other things, efficacy, cost, convenience of storage and
distribution, breadth of approved use, side-effect profile and
durability of immune response; the timing of and BioNTech’s ability
to obtain and maintain regulatory approval for BioNTech's product
candidates; BioNTech’s and its counterparties’ ability to manage
and source necessary resources; BioNTech’s ability to identify
research opportunities and discover and develop investigational
medicines; the ability and willingness of BioNTech’s third-party
collaborators to continue research and development activities
relating to BioNTech’s development candidates and investigational
medicines; BioNTech’s and its collaborators’ ability to
commercialize and market its product candidates, if approved;
BioNTech’s ability to manage its development and expansion;
regulatory developments in the United States and other countries;
BioNTech’s ability to effectively scale its production capabilities
and manufacture its product candidates; and other factors not known
to BioNTech at this time.
You should review the risks and uncertainties
described under the heading “Risk Factors” in BioNTech's Report on
Form 6-K for the period ended September 30, 2023, and in subsequent
filings made by BioNTech with the SEC, which are available on the
SEC’s website at www.sec.gov. Except as required by law, BioNTech
disclaims any intention or responsibility for updating or revising
any forward-looking statements contained in this press release in
the event of new information, future developments or otherwise.
These forward-looking statements are based on BioNTech’s current
expectations and speak only as of the date hereof.
CONTACTS
Investor Relations
Victoria Meissner, M.D.
+1 617 528 8293
Investors@biontech.de
Media Relations
Jasmina Alatovic
+49 (0)6131 9084 1513
Media@biontech.de
Biontech (LSE:0A3M)
Historical Stock Chart
From Apr 2024 to May 2024
Biontech (LSE:0A3M)
Historical Stock Chart
From May 2023 to May 2024